Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

doi:10.5493/wjem.125753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 125753
Published online Sep 20, 2026. doi: 10.5493/wjem.125753

Table 1 Baseline characteristics of patients with relapsed or refractory multiple myeloma who underwent apheresis for planned chimeric antigen receptor T-cell infusion, n (%)

Characteristic	CAR-T infused (n = 87)	Not infused (n = 12)	P value	Test
Age at apheresis, year, median (range)	67.7 (36.7-81.7)	70.2 (42.6-83.7)	0.415	Wilcoxon
Sex	Not evaluable (missing 87/87)	Not evaluable (missing 12/12)	-	-
Plasma cell leukaemia	3/87 (3.4)	3/12 (25.0)	0.017	Fisher
Extramedullary disease	17/87 (19.5)	9/12 (75.0)	< 0.001	Fisher
High-risk cytogenetics¹	29/85 (34.1)	4/11 (36.4)	0.88	Fisher
Missing	2	1	-	-
R-ISS stage	-	-	0.19	Fisher
I	11/66 (16.7)	1/11 (9.1)	-	-
II	52/66 (78.8)	8/11 (72.7)	-	-
III	3/66 (4.5)	2/11 (18.2)	-	-
Not evaluable	21	1	-	-
Prior lines of therapy, median (range)	5 (2-19)	5 (4-8)	0.431	Wilcoxon
Prior autologous or allogeneic transplant	81/87 (93.1)	10/12 (83.3)	0.24	Fisher
Bridging therapy after apheresis	33/87 (37.9)	5/12 (41.7)	0.80	Fisher
Apheresis-to-infusion interval, days, median (IQR; range)	54 (46-62; 37-202), n = 84²	Not applicable	-	-
Lymphodepleting regimen
Fludarabine/cyclophosphamide	43/87 (49.4)	-	-	-
Bendamustine	44/87 (50.6)	-	-	-
Intended/administered CAR-T product	-	-	0.55	Fisher
Ciltacabtagene autoleucel	45/87 (51.7)	6/12 (50.0)	-	-
Idecabtagene vicleucel	42/87 (48.3)	6/12 (50.0)	-	-

¹High-risk cytogenetics.

²Apheresis-to-infusion interval data were not evaluable/missing for 3 of the 87 infused patients.

CAR-T: Chimeric antigen receptor T-cell; R-ISS: Revised International Staging System; IQR: Interquartile range.

Full Size Table

Citation: Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753
URL: https://www.wjgnet.com/2220-315x/full/v16/i3/125753.htm
DOI: https://dx.doi.org/10.5493/wjem.125753

Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753 [DOI: 10.5493/wjem.125753]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.